Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents.
Roddy, Julianna V F
Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents. [electronic resource] - American journal of clinical oncology Feb 2010 - 36-42 p. digital
Publication Type: Journal Article; Multicenter Study
1537-453X
10.1097/COC.0b013e31819cccaf doi
Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors--adverse effects
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Bevacizumab
Colorectal Neoplasms--drug therapy
Drug Therapy, Combination
Erythropoietin--adverse effects
Female
Hemoglobins--metabolism
Humans
Male
Middle Aged
Neoplasm Staging
Pilot Projects
Prognosis
Recombinant Proteins
Retrospective Studies
Survival Rate
Thromboembolism--chemically induced
Vascular Endothelial Growth Factor A--antagonists & inhibitors
Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents. [electronic resource] - American journal of clinical oncology Feb 2010 - 36-42 p. digital
Publication Type: Journal Article; Multicenter Study
1537-453X
10.1097/COC.0b013e31819cccaf doi
Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors--adverse effects
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Bevacizumab
Colorectal Neoplasms--drug therapy
Drug Therapy, Combination
Erythropoietin--adverse effects
Female
Hemoglobins--metabolism
Humans
Male
Middle Aged
Neoplasm Staging
Pilot Projects
Prognosis
Recombinant Proteins
Retrospective Studies
Survival Rate
Thromboembolism--chemically induced
Vascular Endothelial Growth Factor A--antagonists & inhibitors